M. Powers

Favorable Clinician Acceptability of Telehealth as Part of the Cystic Fibrosis Care Model during the COVID-19 Pandemic

G. Sawicki, J. Bailey, G. Solomon, 2021, Annals of the American Thoracic Society.

Changes in Lung Clearance Index in Preschool-aged Patients with Cystic Fibrosis Treated with Ivacaftor (GOAL): A Clinical Trial.

M. Rosenfeld, S. Donaldson, F. Ratjen, 2018, American Journal of Respiratory and Critical Care Medicine.

A national registry for childhood interstitial and diffuse lung diseases in the United States.

R. Deterding, J. Hagood, L. Young, 2018, Rare ILD/DPLD.

Journal of Cystic Fibrosis

P. Ryan, M. Powers, Davis Jaclyn, 2022 .

The US national registry for childhood interstitial and diffuse lung disease: Report of study design and initial enrollment cohort.

A. Hamvas, R. Deterding, C. Conrad, 2023, Pediatric pulmonology.

Long-term follow-up of a cohort of children with alpha-1-antitrypsin deficiency.

A. Buist, J. Eisenberg, E. Moe, 1990, The Journal of pediatrics.

Changes in Lung Clearance Index in Preschool-aged Patients with Cystic Fibrosis Treated with Ivacaftor (GOAL): A Clinical Trial.

M. Rosenfeld, S. Donaldson, F. Ratjen, 2018, American journal of respiratory and critical care medicine.

Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ≥6 Years with Cystic Fibrosis and At Least One F508del Allele: A Phase 3, Open-Label Clinical Trial.

S. McColley, D. Waltz, J. Davies, 2023, American journal of respiratory and critical care medicine.